Xeris Biopharma Holdings, Inc.
Xeris Biopharma provides therapies for chronic endocrine and neurological diseases. The company commercializes three FDA-approved products: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia in diabetes patients, and Keveyis for Primary Periodic Paralysis.
Xeris Biopharma Holdings, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.20B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 |
Spoken Alpha tracks XERS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 60% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for XERS.
$ curl https://api.spokenalpha.com/v1/companies/XERSFAQ
Spoken Alpha indexes XERS's earnings call transcripts at https://spokenalpha.com/companies/XERS. Each call links to attributed speakers and parsed analyst Q&A. Xeris Biopharma Holdings, Inc.'s own investor relations page is at https://www.xerispharma.com/investor-relations.
Xeris Biopharma Holdings, Inc. (XERS) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
Xeris Biopharma Holdings, Inc. (XERS) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| 2026-08-05 |
| — |
| $0.02 |
| — |
| — |
| — |
| — |
EODHD |
Source: EODHD. XERS reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.25 | $2.12 | +6.3% | +0.7% | -1.5% |
| Q4 FY2026 | $2.13 | $2.09 | +1.9% | +3.1% | +2.7% |
| Q3 FY2026 | $2.08 | $2.00 | +3.8% | -0.4% | -2.1% |
| Q2 FY2026 | $1.97 | $1.98 | -0.7% | +4.4% | +2.0% |
| Q1 FY2025 | $2.32 | $2.25 | +2.9% | -3.2% | -2.2% |
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
| Q4 FY2025 |
| $2.23 |
| $2.00 |
| +11.3% |
| -3.3% |
| -1.2% |
| Q3 FY2025 | $2.33 | $2.05 | +13.7% | +4.9% | +6.5% |
| Q2 FY2025 | $2.20 | $2.22 | -0.7% | -1.5% | -0.8% |
| Q1 FY2024 | $2.11 | $2.06 | +2.2% | +1.2% | +4.2% |
| Q4 FY2024 | $2.32 | $2.20 | +5.3% | +5.2% | +3.3% |